Chemours Valuation
Is CC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CC ($18.85) is trading below our estimate of fair value ($80.79)
Significantly Below Fair Value: CC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CC?
Key metric: As CC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is CC's PE Ratio? | |
|---|---|
| PE Ratio | 37.1x |
| Earnings | US$76.00m |
| Market Cap | US$2.82b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | 8.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does CC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.9x | ||
KWR Quaker Chemical | 23.8x | 18.3% | US$2.9b |
SXT Sensient Technologies | 36.5x | 20.2% | US$3.2b |
MTX Minerals Technologies | 16.6x | 23.1% | US$2.5b |
ASH Ashland | 18.7x | 5.0% | US$3.7b |
CC Chemours | 37.1x | n/a | US$2.8b |
Price-To-Earnings vs Peers: CC is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the peer average (23.9x).
Price to Earnings Ratio vs Industry
How does CC's PE Ratio compare vs other companies in the US Chemicals Industry?
Price-To-Earnings vs Industry: CC is expensive based on its Price-To-Earnings Ratio (37.1x) compared to the US Chemicals industry average (22.6x).
Price to Earnings Ratio vs Fair Ratio
What is CC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 37.1x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CC's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$18.85 | US$24.90 +32.1% | 19.7% | US$35.00 | US$18.00 | n/a | 10 |
| Nov ’25 | US$17.82 | US$25.50 +43.1% | 20.9% | US$35.00 | US$18.00 | n/a | 10 |
| Oct ’25 | US$19.71 | US$26.50 +34.4% | 21.7% | US$35.00 | US$18.00 | n/a | 10 |
| Sep ’25 | US$19.44 | US$27.20 +39.9% | 20.5% | US$35.00 | US$18.00 | n/a | 10 |
| Aug ’25 | US$23.31 | US$29.90 +28.3% | 13.0% | US$35.00 | US$25.00 | n/a | 10 |
| Jul ’25 | US$22.62 | US$30.00 +32.6% | 13.7% | US$37.00 | US$25.00 | n/a | 10 |
| Jun ’25 | US$24.82 | US$30.22 +21.8% | 11.6% | US$35.00 | US$25.00 | n/a | 9 |
| May ’25 | US$26.00 | US$31.27 +20.3% | 14.3% | US$40.00 | US$26.00 | n/a | 10 |
| Apr ’25 | US$28.74 | US$28.78 +0.1% | 21.9% | US$40.00 | US$19.00 | n/a | 9 |
| Mar ’25 | US$20.78 | US$30.78 +48.1% | 19.9% | US$40.00 | US$19.00 | n/a | 9 |
| Feb ’25 | US$30.77 | US$33.67 +9.4% | 17.9% | US$45.00 | US$26.00 | n/a | 9 |
| Jan ’25 | US$31.54 | US$33.22 +5.3% | 18.9% | US$45.00 | US$26.00 | n/a | 9 |
| Dec ’24 | US$29.68 | US$32.22 +8.6% | 16.7% | US$40.00 | US$26.00 | n/a | 9 |
| Nov ’24 | US$23.94 | US$32.78 +36.9% | 16.8% | US$41.00 | US$26.00 | US$17.82 | 9 |
| Oct ’24 | US$28.05 | US$40.30 +43.7% | 13.7% | US$53.00 | US$33.00 | US$19.71 | 10 |
| Sep ’24 | US$34.99 | US$39.55 +13.0% | 15.3% | US$53.00 | US$29.00 | US$19.44 | 11 |
| Aug ’24 | US$36.86 | US$39.45 +7.0% | 15.3% | US$53.00 | US$29.00 | US$23.31 | 11 |
| Jul ’24 | US$36.89 | US$37.55 +1.8% | 25.7% | US$64.00 | US$25.00 | US$22.62 | 11 |
| Jun ’24 | US$27.11 | US$37.09 +36.8% | 20.3% | US$54.00 | US$25.00 | US$24.82 | 11 |
| May ’24 | US$29.76 | US$38.00 +27.7% | 18.5% | US$54.00 | US$25.00 | US$26.00 | 11 |
| Apr ’24 | US$29.94 | US$38.36 +28.1% | 17.1% | US$52.00 | US$27.00 | US$28.74 | 11 |
| Mar ’24 | US$34.84 | US$38.42 +10.3% | 17.5% | US$52.00 | US$27.00 | US$20.78 | 12 |
| Feb ’24 | US$36.33 | US$36.00 -0.9% | 21.9% | US$52.00 | US$24.00 | US$30.77 | 12 |
| Jan ’24 | US$30.62 | US$35.00 +14.3% | 23.5% | US$55.00 | US$24.00 | US$31.54 | 12 |
| Dec ’23 | US$31.25 | US$33.33 +6.7% | 18.4% | US$48.00 | US$24.00 | US$29.68 | 12 |
| Nov ’23 | US$28.71 | US$33.42 +16.4% | 19.7% | US$50.00 | US$24.00 | US$23.94 | 12 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Trinseo
US$117.5m
Operates as a specialty material solutions provider in the United States, Europe, the Asia-Pacific, and internationally.
TSE
US$3.32
7D
-8.3%
1Y
-48.8%
CMOC Group
HK$167.3b
Engages in the mining, beneficiation, smelting, and refining of base and rare metals.
CMCL.F
HK$0.76
7D
0%
1Y
37.8%
Chemtrade Logistics Income Fund
CA$1.4b
Offers industrial chemicals and services in Canada, the United States, and South America.
CGIF.F
CA$8.30
7D
5.2%
1Y
31.5%